When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ImmunoGen (NASDAQ:IMGN) slumps 43% premarket on light volume (at this point) in response to its announcement that the Phase 3 FORWARD I study evaluating antibody-drug conjugate mirvetuximab soravtansine compared to chemo in folate receptor alpha-positive, platinum-resistant ovarian cancer patients failed to achieve the primary endpoint of progression-free survival (PFS) in either the entire study population or the pre-specified subset of patients with high folate receptor alpha expression.
More news on: ImmunoGen, Inc., Healthcare stocks news, Stocks on the move,